- Home
- MRM vs SLXN Comparison
MRM vs SLXN Comparison
Compare MRM & SLXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRM
- SLXN
- Stock Information
- Founded
- MRM 2000
- SLXN 2008
- Country
- MRM Japan
- SLXN Israel
- Employees
- MRM N/A
- SLXN N/A
- Industry
- MRM Other Consumer Services
- SLXN
- Sector
- MRM Consumer Discretionary
- SLXN
- Exchange
- MRM Nasdaq
- SLXN NYSE
- Market Cap
- MRM 5.9M
- SLXN 6.9M
- IPO Year
- MRM 2020
- SLXN N/A
- Fundamental
- Price
- MRM $1.55
- SLXN $1.04
- Analyst Decision
- MRM
- SLXN Strong Buy
- Analyst Count
- MRM 0
- SLXN 1
- Target Price
- MRM N/A
- SLXN $5.00
- AVG Volume (30 Days)
- MRM 856.7K
- SLXN 1.2M
- Earning Date
- MRM 05-20-2025
- SLXN 05-13-2025
- Dividend Yield
- MRM N/A
- SLXN N/A
- EPS Growth
- MRM 27.65
- SLXN N/A
- EPS
- MRM 0.18
- SLXN N/A
- Revenue
- MRM $52,786,758.00
- SLXN N/A
- Revenue This Year
- MRM N/A
- SLXN N/A
- Revenue Next Year
- MRM N/A
- SLXN N/A
- P/E Ratio
- MRM $8.55
- SLXN N/A
- Revenue Growth
- MRM 21.55
- SLXN N/A
- 52 Week Low
- MRM $0.34
- SLXN $0.58
- 52 Week High
- MRM $8.39
- SLXN $41.85
- Technical
- Relative Strength Index (RSI)
- MRM 63.68
- SLXN N/A
- Support Level
- MRM $1.13
- SLXN N/A
- Resistance Level
- MRM $1.63
- SLXN N/A
- Average True Range (ATR)
- MRM 0.27
- SLXN 0.00
- MACD
- MRM 0.04
- SLXN 0.00
- Stochastic Oscillator
- MRM 63.30
- SLXN 0.00
About MRM MEDIROM Healthcare Technologies Inc.
MEDIROM Healthcare Technologies Inc provides health services. The company is a franchiser and operator of healthcare salons and operates in segments namely Relaxation Salon, Digital Preventative Healthcare, and Luxury Beauty Segment. The company generates a majority of its revenue from the Relaxation Salon business segment. Geographically, the company generates a maximum share of its revenue from Japan.
About SLXN BIOMOTION SCIENCES
Silexion Therapeutics Corp a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for KRAS-driven cancers. The KRAS gene is an oncogene that is involved in the regulation of cell division as a result of its ability to relay external signals into the cell. Its product candidate, SIL204, consists of locally administered small interfering RNAs, or siRNA, in a solution, as a first-line treatment of locally advanced pancreatic cancer patients, or LAPC, in combination with standard-of-care chemotherapy. It is currently focused on treatment for pancreatic cancer tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected and are non-resectable, i.e. it is not able to be surgically removed.